James T. Williams

Supreme Court Decision on Scope of Patent Protection: Supreme Court Holds Pharmaceutical Treatment Method Without “Inventive” Insight Unpatentable as a Law of Nature
Garrard R. Beeney,Adam R. Brebner,Marc De Leeuw,John Evangelakos,Nader A. Mousavi,Keith A. Pagnani,James T. Williams, March 23, 2012
In a decision that is likely to have significant implications across the healthcare spectrum, including biotech, diagnostics and medical devices, on March 20, 2012, the U.S. Supreme Court held that two patents claiming methods for optimizing the therapeutic efficacy of drugs by monitoring...

Congress Passes Historic Patent Reform Legislation: America Invents Act Transitions U.S. Patent System from a “First-to-Invent” to “First-Inventor-to-File” System, Overhauls Post-Issue Review Proceedings and Provides Other Significant Reforms; Expected to Become Law by End of September
Garrard R. Beeney,Adam R. Brebner,Marc De Leeuw,David B. Tulchin,James T. Williams, September 21, 2011
On September 8, 2011, the U.S. Senate approved a landmark bill to reform the nation’s patent system, entitled the “Leahy-Smith America Invents Act,” which was previously passed by the U.S. House of Representatives on June 23, 2011. President Obama is expected to sign the bill into...

Patent Law: Federal Circuit Rules Isolated DNA May Be Patented
Garrard R. Beeney,Marc De Leeuw,Nader A. Mousavi,David B. Tulchin,James T. Williams, August 9, 2011
On July 29, 2011, in a highly anticipated opinion, a divided three-judge panel of the United States Court of Appeals for the Federal Circuit held that isolated DNA molecules are patentable subject matter under § 101 of the Patent Act. All three judges on the Federal Circuit panel also ruled...